IO Frontiers World 2019


Alise Reicin

Dr Alise Reicin

SVP, Head of Global Clinical Development, EMD Serono

Alise Reicin, MD, is Senior Vice President and Head of Global Clinical Development in R&D at EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany.

Reicin leads the Global Clinical Development organization, including the Clinical Development Therapeutic Areas; Evidence Value and Development; Biostatistics; Clinical Operations; and both the Japan and China R&D Hubs. In this capacity, she also leads Merck KGaA, Darmstadt, Germany’s portfolio of pipeline programs.

Prior to joining Merck KGaA, Darmstadt, Germany, Reicin served as Vice President, Project and Pipeline Leadership, Oncology Franchise at Merck. She led Merck’s PD-1 program and oversaw the initial development and filing activities worldwide, including the first approval in the US. She also managed program leaders across early and late oncology product development teams. During her career at Merck she held multiple leadership roles in both the Early and Late Clinical Development where she oversaw the development of compounds across a broad range of therapeutic areas including immunology, respiratory, pain, muscle and bone disease. She oversaw over 15 successful NDAs and WMAs during this time. She was a member of the Global Development Leadership Team.

Before joining Merck, Reicin was a faculty member at Columbia Medical School, and a physician and researcher at Columbia Presbyterian Hospital.

Reicin has a degree in biochemistry from Barnard College of Columbia University (summa cum laude). She received her Medical Degree from Harvard Medical School (cum laude) where she was enrolled in the Health Sciences and Technology program with MIT (Massachusetts Institute of Technology).

In her role as Head of Global Clinical Development at Merck KGaA, Darmstadt, Germany, Reicin reports to the head of Global R&D and serves as a member of the R&D Executive Leadership Team. 

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy